Consensus Boston Scientific Corporation

Equities

BSX

US1011371077

Market Closed - Nyse Other stock markets 04:00:02 2024-04-18 pm EDT			5-day change	1st Jan Change
67.42 ^USD	-0.79%		-2.06%	+16.62%

Apr. 17	FDA classifies recall of Boston Scientific device as 'most serious'	RE
Apr. 17	FDA classifies recall of Boston Scientific device to treat hemorrhaging as 'most serious'	RE

Evolution of the average Target Price on Boston Scientific Corporation

Price target over the last 5 years

History of analyst recommendation changes

fd.wemRBhxaxbgrlZjapqdwfWvh8bTLPhLXYTnptcZPo-c.rdCpMk87ssBn3-3o3_QWOhylmsOGYXWVIHXEwKM57LOxj8NnRD2D_XT33Q~6eb41930432d2aef02ab902dbc23a211

Analyst Recommendations on Boston Scientific Corporation

Baird Adjusts Boston Scientific Price Target to $79 From $72	Apr. 17	MT
Truist Securities Adjusts Boston Scientific Price Target to $79 From $73, Buy Rating Kept	Apr. 15	MT
BTIG Adjusts Boston Scientific's Price Target to $74 From $72	Apr. 15	MT
RBC Raises Price Target on Boston Scientific to $78 From $70, Keeps Outperform Rating	Apr. 15	MT
Argus Raises Boston Scientific's Price Target to $80 From $69, Keeps Buy Rating	Apr. 03	MT
Citigroup Adjusts Price Target on Boston Scientific to $79 From $71, Keeps Buy Rating	Apr. 03	MT
Boston Scientific Insider Sold Shares Worth $1,133,069, According to a Recent SEC Filing	Apr. 03	MT
Boston Scientific Insider Sold Shares Worth $477,777, According to a Recent SEC Filing	Apr. 03	MT
Boston Scientific Insider Sold Shares Worth $963,930, According to a Recent SEC Filing	Mar. 20	MT
TD Cowen Raises Boston Scientific's Price Target to $77 From $65, Maintains Outperform Rating	Mar. 07	MT
ANALYST RECOMMENDATIONS : Block, Quanta Services, Nvidia, Home Depot, Nutrien...	Feb. 23
Raymond James Adjusts Price Target on Boston Scientific to $73 From $67, Maintains Strong Buy Rating	Feb. 01	MT
Jefferies Adjusts Price Target on Boston Scientific to $74 From $62, Maintains Buy Rating	Feb. 01	MT
JPMorgan Chase Adjusts Price Target on Boston Scientific to $72 From $60, Maintains Overweight Rating	Feb. 01	MT
Mizuho Securities Upgrades Boston Scientific to Buy From Neutral, Raises Price Target to $80 From $65	Feb. 01	MT
Wells Fargo Raises Price Target on Boston Scientific to $72 From $70, Maintains Overweight Rating	Feb. 01	MT
Truist Securities Raises Price Target on Boston Scientific to $73 From $70, Keeps Buy Rating	Feb. 01	MT
Canaccord Genuity Adjusts Price Target on Boston Scientific to $81 From $77, Keeps Buy Rating	Feb. 01	MT
Needham Adjusts Boston Scientific's Price Target to $71 From $60, Keeps Buy Rating	Feb. 01	MT
Oppenheimer Raises Boston Scientific Price Target to $68 From $58, Maintains Perform Rating	Feb. 01	MT
RBC Lifts Price Target on Boston Scientific to $70 From $67 Amid 'Solid Q4 Beat,' Says 2024 Guidance Looks Conservative, Keeps Outperform Rating	Feb. 01	MT
Which Jerome will we get?	Jan. 31
UBS Adjusts Boston Scientific Price Target to $71 From $67, Maintains Buy Rating	Jan. 22	MT
RBC Lifts Price Target on Boston Scientific to $67 From $61, Cites Stock Runup, Growth Opportunities Amid Axonics Deal, Outperform Kept	Jan. 09	MT
Investors lower their expectations	Jan. 08

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

67.96 USD

Average target price

73.4 USD

Spread / Average Target

+8.01%

High Price Target

81 USD

Spread / Highest target

+19.19%

Low Price Target

61 USD

Spread / Lowest Target

-10.24%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Boston Scientific Corporation

Baird
Truist Securities
BTIG
RBC Capital Markets
Argus
Citigroup
TD Cowen
Raymond James
Jefferies & Co.
JPMorgan Chase
Mizuho Securities
Wells Fargo Securities
Canaccord Genuity
Needham & Co.
Oppenheimer
UBS
Morgan Stanley
Stifel Nicolaus
Bernstein
Barclays
Evercore ISI
Piper Sandler
CL King
Deutsche Bank Securities
Goldman Sachs
Wolfe Research
BofA Securities
SVB Leerink
Credit Suisse
Atlantic Equities

Ratings for Boston Scientific Corporation

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar